Antithrombotic Trialists ATT Collaboration Lancet 2009 373 1849

Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009; 373: 1849 -60

Design and eligibility criteria of primary prevention trials Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009; 373: 1849 -60

Serious vascular events in primary prevention trials-proportional effects of aspirin allocation Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009; 373: 1849 -60

Serious vascular events in primary prevention Trials-subgroup analyses ATT Collaboration. Lancet 2009; 373: 1849 -60

Comparison of proportional and absolute effects of aspirin in primary and secondary prevention trials Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009; 373: 1849 -60

Selected outcomes in primary and secondary prevention trials of aspirin, by sex ATT Collaboration. Lancet 2009; 373: 1849 -60

Stroke subtypes in primary and secondary prevention trials ATT Collaboration. Lancet 2009; 373: 1849 -60

Mortality by cause in primary prevention trials Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009; 373: 1849 -60

Rate ratios (95% CI) associated with risk factors for selected outcomes in people with no known vascular disease in primary prevention trials Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009; 373: 1849 -60

Predicted 5 -year absolute eff ects of allocation to aspirin in different categories of age and sex in the primary and secondary prevention trials (ignoring nonvascular mortality) ATT Collaboration. Lancet 2009; 373: 1849 -60

Predicted 5 -year absolute effects of allocation to aspirin in the primary prevention trials in different categories of 5 -year risk (if untreated) of coronary heart disease (CHD) (ignoring nonvascular mortality) ATT Collaboration. Lancet 2009; 373: 1849 -60